LAVAL, Quebec, May 31, 2016 /CNW/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX)
("Valeant" or the "Company") today announced that it plans to host
a conference call and live webcast on June
7, 2016 to discuss first quarter 2016 financial
results.
Conference Call Details:
Date
|
June 7,
2016
|
Time
|
8:00 a.m.
ET
|
Webcast
|
http://ir.valeant.com/events-and-presentations
|
Participant Event
Dial-in
|
(877) 876-8393 (North
America)
|
|
(973) 200-3961
(International)
|
Participant
Passcode
|
88949054
|
Replay
Dial-in
|
(855) 859-2056 (North
America)
|
|
(404) 537-3406
(International)
|
Replay
Passcode
|
88949054
(Replay available until 06/15/2016)
|
The Company also provided an update on regulatory matters. In
response to an application made by the Company in connection with
the Company's previously announced delay in filing its interim
financial statements for the quarter ended March 31, 2016 (together with the required
associated filings, the "Canadian Required Filings") with Canadian
securities regulators until after the May
15, 2016 filing deadline, the Autorité des marchés
financiers (the company's principal securities regulator in
Canada) issued a customary
management cease trade order ("MCTO") on May
17, 2016 relating to the trading in securities of the
Company by the Company's CEO and CFO and each other member of the
Company's board of directors. Keeping with common practice, an MCTO
relating to a director of the Company who is resident in
Ontario was issued by the Ontario
Securities Commission on that same date. The MCTOs do not
affect the ability of other shareholders to trade in the securities
of the Company.
In connection with the issuance of the MCTOs, and in accordance
with its obligation to provide bi-weekly updates under the
alternative information guidelines set out in National Policy
12-203 Cease Trade Orders for Continuous Disclosure
Defaults, the Company confirms that it has fulfilled its stated
intentions regarding compliance with such alternative information
guidelines and that, except as previously disclosed, there have
been no material changes to the information relating to the
Company's delay in making the Canadian Required Filings or its
other required filings under applicable Canadian securities laws or
otherwise concerning the affairs of the Company.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements,
including, but not limited to, statements regarding Valeant's
financial reporting and future prospects. Forward-looking
statements may generally be identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could,"
"would," "may," "will," "believes," "estimates," "potential,"
"target," or "continue" and variations or similar expressions.
These statements are based upon the current expectations and
beliefs of management and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. These risks
and uncertainties include, but are not limited to, risks and
uncertainties discussed in the Company's most recent annual or
quarterly report and detailed from time to time in Valeant's other
filings with the Securities and Exchange Commission and the
Canadian Securities Administrators, which factors are incorporated
herein by reference. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof.
Valeant undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this press release or to reflect actual outcomes,
unless required by law.
Contact Information:
Laurie W. Little
laurie.little@valeant.com
or
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-to-hold-conference-call-on-june-7-2016-300277236.html
SOURCE Valeant Pharmaceuticals International, Inc.